<description>&lt;p class="MsoNormal" style= "margin-bottom: 0in; line-height: normal;"&gt;&lt;em&gt;&lt;span style= "font-size: 10.0pt; font-family: 'Trebuchet MS',sans-serif;"&gt;In this podcast episode, Dr. Christine Ibilibor meets with Dr. Jean-Paul De La O, a Senior Principal Medical Affairs Director at Exact Sciences, to talk about how comprehensive DNA and RNA sequencing of tumors has become easier, faster and more actionable for oncologists. The pair also discuss Exact Sciences' retrospective analysis of over 10,000 solid tumor samples profiled with the OncoExTra® test, and what the results revealed about biomarker testing.&lt;/span&gt;&lt;/em&gt; &lt;span style= "font-size: 10.0pt; font-family: 'Trebuchet MS',sans-serif;"&gt; &lt;/span&gt;&lt;/p&gt;</description>

OncTimes Talk

Oncology Times

Results from OncoExTra® Testing of 10K Tumor Samples Show the Next Generation of Sequencing

JAN 5, 202612 MIN
OncTimes Talk

Results from OncoExTra® Testing of 10K Tumor Samples Show the Next Generation of Sequencing

JAN 5, 202612 MIN

Description

In this podcast episode, Dr. Christine Ibilibor meets with Dr. Jean-Paul De La O, a Senior Principal Medical Affairs Director at Exact Sciences, to talk about how comprehensive DNA and RNA sequencing of tumors has become easier, faster and more actionable for oncologists. The pair also discuss Exact Sciences' retrospective analysis of over 10,000 solid tumor samples profiled with the OncoExTra® test, and what the results revealed about biomarker testing.